Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven T Chen

Showing results (121-130 of 153) with videos related to

Pageof 16
Sort By:
JAMA Dermatology|March 24, 2021
Patterns of Cutaneous and Noncutaneous Immune-Related Adverse Events Among Patients With Advanced CancerLeah L Thompson, Nira A Krasnow, Michael S Chang, et al.
JAAD Case Reports|November 8, 2021
Cutaneous mucormycosis arising in the skin folds of immunocompromised patients: A case seriesRenajd Rrapi, Sidharth Chand, Rebecca Gaffney, et al.
Journal of the American Academy of Dermatology|September 18, 2025
Vulvovaginal involvement in Stevens-Johnson syndrome/toxic epidermal necrolysis: A retrospective review at a tertiary care center (2016-2024)Beatrix B Thompson, Natalie M Baker, Sydney Corey, et al.
Journal of the American Academy of Dermatology|August 10, 2025
Type 2 immunity links eczematous and lichenoid eruptions caused by immune checkpoint inhibitorsMarjan Azin, Parisa Farokh, Alexander McGarry, et al.
Journal of the American Academy of Dermatology|February 22, 2022
Association between serum lactate dehydrogenase and cutaneous immune-related adverse events among patients on immune checkpoint inhibitors for advanced melanomaMaria S Asdourian, Tracey S Otto, Ted V Jacoby, et al.
Journal of the American Academy of Dermatology|March 16, 2021
Prognostic significance of cutaneous immune-related adverse events in patients with melanoma and other cancers on immune checkpoint inhibitorsLeah L Thompson, Michael S Chang, Nicole J Polyakov, et al.
International Journal of Dermatology|May 19, 2023
Detection of novel therapies using a multi-national, multi-institutional registry of cutaneous immune-related adverse events and managementRohan Mital, Tracey S Otto, Andrei Savu, et al.
The British Journal of Dermatology|February 17, 2024
Cancer type and histology influence cutaneous immunotherapy toxicities: a multi-institutional cohort studyGuihong Wan, Sara Khattab, Bonnie W Leung, et al.
Journal of the American Academy of Dermatology|October 14, 2023
Pre-existing inflammatory disease predicts cutaneous immunotherapy toxicity development: A multi-institutional cohort studyGuihong Wan, Nga Nguyen, Bonnie W Leung, et al.
Medrxiv : the Preprint Server for Health Sciences|September 11, 2023
Pre-Existing Inflammatory Disease Predicts Cutaneous Immunotherapy Toxicity Development: A Multi-Institutional Cohort StudyGuihong Wan, Nga Nguyen, Bonnie W Leung, et al.
Pageof 16

Showing results (121-130 of 153) with videos related to

Sort By:
Pageof 16
JAMA Dermatology|March 24, 2021
Patterns of Cutaneous and Noncutaneous Immune-Related Adverse Events Among Patients With Advanced CancerLeah L Thompson, Nira A Krasnow, Michael S Chang, et al.
JAAD Case Reports|November 8, 2021
Cutaneous mucormycosis arising in the skin folds of immunocompromised patients: A case seriesRenajd Rrapi, Sidharth Chand, Rebecca Gaffney, et al.
Journal of the American Academy of Dermatology|September 18, 2025
Vulvovaginal involvement in Stevens-Johnson syndrome/toxic epidermal necrolysis: A retrospective review at a tertiary care center (2016-2024)Beatrix B Thompson, Natalie M Baker, Sydney Corey, et al.
Journal of the American Academy of Dermatology|August 10, 2025
Type 2 immunity links eczematous and lichenoid eruptions caused by immune checkpoint inhibitorsMarjan Azin, Parisa Farokh, Alexander McGarry, et al.
Journal of the American Academy of Dermatology|February 22, 2022
Association between serum lactate dehydrogenase and cutaneous immune-related adverse events among patients on immune checkpoint inhibitors for advanced melanomaMaria S Asdourian, Tracey S Otto, Ted V Jacoby, et al.
Journal of the American Academy of Dermatology|March 16, 2021
Prognostic significance of cutaneous immune-related adverse events in patients with melanoma and other cancers on immune checkpoint inhibitorsLeah L Thompson, Michael S Chang, Nicole J Polyakov, et al.
International Journal of Dermatology|May 19, 2023
Detection of novel therapies using a multi-national, multi-institutional registry of cutaneous immune-related adverse events and managementRohan Mital, Tracey S Otto, Andrei Savu, et al.
The British Journal of Dermatology|February 17, 2024
Cancer type and histology influence cutaneous immunotherapy toxicities: a multi-institutional cohort studyGuihong Wan, Sara Khattab, Bonnie W Leung, et al.
Journal of the American Academy of Dermatology|October 14, 2023
Pre-existing inflammatory disease predicts cutaneous immunotherapy toxicity development: A multi-institutional cohort studyGuihong Wan, Nga Nguyen, Bonnie W Leung, et al.
Medrxiv : the Preprint Server for Health Sciences|September 11, 2023
Pre-Existing Inflammatory Disease Predicts Cutaneous Immunotherapy Toxicity Development: A Multi-Institutional Cohort StudyGuihong Wan, Nga Nguyen, Bonnie W Leung, et al.
Pageof 16